{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T07:59:52Z","timestamp":1787817592254,"version":"build-2784847793"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p><jats:sup>18<\/jats:sup>F-Labeled Fluorodeoxyglucose-Positron Emission Tomography (<jats:sup>18<\/jats:sup>F-FDG PET) is a molecular imaging tool commonly used in practice for the assessment of many cancers. Thanks to its properties, its use has been progressively extended to numerous inflammatory conditions, including chronic inflammatory rheumatism (CIR) such as rheumatoid arthritis (RA), spondylarthritis (SpAs) and polymyalgia rheumatica (PMR). <jats:sup>18<\/jats:sup>F-FDG PET is currently not recommended for the diagnostic of CIRs. However, this whole-body imaging tool has emerged in clinical practice, providing a general overview of systemic involvement occurring in CIRs. Numerous studies have highlighted the capacity of <jats:sup>18<\/jats:sup>F-FDG PET to detect articular and extra articular involvements in RA and PMR. However, the lack of specificity of <jats:sup>18<\/jats:sup>F-FDG limits its use for diagnosis purpose. Finally, the key question is the definition of the best way to integrate this whole-body imaging tool in the patient\u2019s management workflow.<\/jats:p>","DOI":"10.3389\/fmed.2022.1070445","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T07:13:51Z","timestamp":1669792431000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["18F-FDG PET molecular imaging: A relevant tool to investigate chronic inflammatory rheumatisms in clinical practice?"],"prefix":"10.3389","volume":"9","author":[{"given":"Marie","family":"Pean De Ponfilly \u2013 Sotier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00eble","family":"Seror","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetane","family":"Nocturne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent L.","family":"Besson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.cpet.2020.06.005","article-title":"PET\/computed tomography scans and PET\/MR imaging in the diagnosis and management of musculoskeletal diseases.","volume":"15","author":"Manhas","year":"2020","journal-title":"PET Clin."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-000950","article-title":"Implementation and role of modern musculoskeletal imaging in rheumatological practice in member countries of EULAR.","volume":"5","author":"Mandl","year":"2019","journal-title":"RMD Open."},{"key":"B3","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1136\/annrheumdis-2017-212649","article-title":"EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice.","volume":"77","author":"Dejaco","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1007\/s00259-018-3973-8","article-title":"FDG-PET\/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC.","volume":"45","author":"Slart","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1007\/s00259-016-3377-6","article-title":"Contribution of (18)F-FDG PET in the diagnostic assessment of fever of unknown origin (FUO): a stratification-based meta-analysis.","volume":"43","author":"Besson","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B6","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1136\/annrheumdis-2012-203158","article-title":"EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis.","volume":"72","author":"Colebatch","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-014-0423-2","article-title":"Clinical value of whole-body PET\/CT in patients with active rheumatic diseases.","volume":"16","author":"Yamashita","year":"2014","journal-title":"Arthritis Res Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1053\/j.semnuclmed.2017.02.005","article-title":"Clinical value of FDG-PET\/CT for the evaluation of rheumatic diseases: rheumatoid arthritis, polymyalgia rheumatica, and relapsing polychondritis.","volume":"47","author":"Kubota","year":"2017","journal-title":"Semin Nucl Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis.","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet."},{"key":"B10","first-page":"117","article-title":"Rheumatoid arthritis and spondyloarthropathies: geographical variations in prevalence in France.","volume":"34","author":"Roux","year":"2007","journal-title":"J Rheumatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1002\/art.42162","article-title":"A risk score to detect subclinical rheumatoid arthritis-associated interstitial lung disease.","volume":"74","author":"Juge","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American college of rheumatology\/European league against rheumatism collaborative initiative.","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007130","article-title":"Diagnostic value of 18F-fluorodeoxyglucose uptake parameters to differentiate rheumatoid arthritis from other types of arthritis.","volume":"96","author":"Bhattarai","year":"2017","journal-title":"Medicine."},{"key":"B14","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jbspin.2012.04.006","article-title":"Similarities and differences in fluorodeoxyglucose positron emission tomography\/computed tomography findings in spondyloarthropathy, polymyalgia rheumatica and rheumatoid arthritis.","volume":"80","author":"Yamashita","year":"2013","journal-title":"Joint Bone Spine."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9614678","article-title":"The combination of 18F-fluorodeoxyglucose positron emission tomography metabolic and clinical parameters can effectively distinguish rheumatoid arthritis and polymyalgia rheumatic.","volume":"2022","author":"Wang","year":"2022","journal-title":"Contrast Media Mol Imaging."},{"key":"B16","first-page":"956","article-title":"Assessment of disease activity in rheumatoid arthritis with (18)F-FDG PET.","volume":"45","author":"Beckers","year":"2004","journal-title":"J Nucl Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00259-012-2282-x","article-title":"Correlation of 18F-FDG PET\/CT assessments with disease activity and markers of inflammation in patients with early rheumatoid arthritis following the initiation of combination therapy with triple oral antirheumatic drugs.","volume":"40","author":"Roivainen","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2967\/jnumed.110.076711","article-title":"18F-FDG PET as a tool to predict the clinical outcome of infliximab treatment of rheumatoid arthritis: an explorative study.","volume":"52","author":"Elzinga","year":"2011","journal-title":"J Nucl Med."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-15-393","article-title":"Evaluation of tocilizumab therapy in patients with rheumatoid arthritis based on FDG-PET\/CT.","volume":"15","author":"Okamura","year":"2014","journal-title":"BMC Musculoskelet Disord."},{"key":"B20","doi-asserted-by":"publisher","first-page":"SI6","DOI":"10.1093\/rheumatology\/keab842","article-title":"18F-FDG PET-CT in rheumatoid arthritis patients tapering TNFi: reliability, validity and predictive value.","volume":"61","author":"Bouman","year":"2022","journal-title":"Rheumatology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/RLU.0000000000003962","article-title":"Potential and most relevant applications of total body PET\/CT imaging.","volume":"47","author":"Alavi","year":"2022","journal-title":"Clin Nucl Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/art.40345","article-title":"Arterial inflammation detected with 18 F-fluorodeoxyglucose-positron emission tomography in rheumatoid arthritis.","volume":"70","author":"Geraldino-Pardilla","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1136\/annrheumdis-2011-200726","article-title":"Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies.","volume":"71","author":"Avina-Zubieta","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02585-w","article-title":"Do biologic therapies reduce aortic inflammation in rheumatoid arthritis patients?","volume":"23","author":"Trang","year":"2021","journal-title":"Arthritis Res Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/art.40771","article-title":"Myocardial inflammation, measured using 18-fluorodeoxyglucose positron emission tomography with computed tomography, is associated with disease activity in rheumatoid arthritis.","volume":"71","author":"Amigues","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jcmg.2014.03.018","article-title":"Arterial 18F-FDG uptake in rheumatoid arthritis correlates with synovial activity.","volume":"7","author":"Emami","year":"2014","journal-title":"JACC Cardiovasc Imaging."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1056\/NEJMra1406182","article-title":"Ankylosing spondylitis and axial spondyloarthritis.","volume":"374","author":"Taurog","year":"2016","journal-title":"N Engl J Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/nrrheum.2009.207","article-title":"Tools for monitoring spondyloarthritis in clinical practice.","volume":"5","author":"van Tubergen","year":"2009","journal-title":"Nat Rev Rheumatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/ard.2010.133645","article-title":"The assessment of spondyloarthritis international society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general.","volume":"70","author":"Rudwaleit","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1007\/s00259-010-1464-7","article-title":"18F-fluoride PET\/CT for detection of sacroiliitis in ankylosing spondylitis.","volume":"37","author":"Strobel","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B31","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2021.105325","article-title":"Use of 18F FDG PET-CT to discriminate polymyalgia rheumatica and atypical spondylarthritis in clinical practice.","volume":"89","author":"Pean de Ponfilly-Sotier","year":"2022","journal-title":"Joint Bone Spine."},{"key":"B32","article-title":"18F- fluoride PET\/CT assessment in patients fulfilling the clinical arm of the ASAS criteria for axial spondyloarthritis. A comparative study with ankylosing spondylitis.","volume":"33","author":"Toussirot","year":"2015","journal-title":"Clin Exp Rheumatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1136\/ard.2005.040345","article-title":"FDG-PET\/CT scan of inflammatory spondylodiscitis lesions in ankylosing spondylitis, and short term evolution during anti-tumour necrosis factor treatment.","volume":"64","author":"Wendling","year":"2005","journal-title":"Ann Rheum Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1056\/NEJMra011913","article-title":"Polymyalgia rheumatica and giant-cell arteritis.","volume":"347","author":"Salvarani","year":"2002","journal-title":"N Engl J Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41584-020-0458-5","article-title":"Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica.","volume":"16","author":"Camellino","year":"2020","journal-title":"Nat Rev Rheumatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/rheumatology\/kel376","article-title":"Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients.","volume":"46","author":"Blockmans","year":"2007","journal-title":"Rheumatology."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1007\/s00259-020-05162-6","article-title":"Diagnostic value of [18F]FDG-PET\/CT in polymyalgia rheumatica: a systematic review and meta-analysis.","volume":"48","author":"van der Geest","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B38","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s12149-018-1269-5","article-title":"Diagnosing polymyalgia rheumatica on 18F-FDG PET\/CT: typical uptake patterns.","volume":"32","author":"Yuge","year":"2018","journal-title":"Ann Nucl Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/rheumatology\/keab483","article-title":"Comparison and validation of FDG-PET\/CT scores for polymyalgia rheumatica.","volume":"61","author":"van der Geest","year":"2022","journal-title":"Rheumatology."},{"key":"B40","article-title":"PET-CT findings in patients with polymylagia rheumatica without symptoms of cranial ischaemia.","volume":"64","author":"Lund Petersen","year":"2017","journal-title":"Dan Med J."},{"key":"B41","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1136\/annrheumdis-2019-216109","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation.","volume":"79","author":"Braaten","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.","volume":"80","author":"Kostine","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217225","article-title":"Features of polymyalgia rheumatica-like syndrome after immune checkpoint inhibitor therapy.","volume":"81","author":"Martin de Fremont","year":"2022","journal-title":"Ann Rheum Dis."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12081961","article-title":"Imaging findings in patients with immune checkpoint inhibitor-induced arthritis.","volume":"12","author":"Ponce","year":"2022","journal-title":"Diagnostics."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218276","article-title":"Management of immune checkpoint inhibitor-induced polymyalgia rheumatica.","volume":"81","author":"van der Geest","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1007\/s00262-020-02803-5","article-title":"Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors.","volume":"70","author":"Zhong","year":"2021","journal-title":"Cancer Immunol Immunother."},{"key":"B47","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s00259-015-3287-z","article-title":"Value of (18)F-FDG PET\/CT for therapeutic assessment of patients with polymyalgia rheumatica receiving tocilizumab as first-line treatment.","volume":"43","author":"Palard-Novello","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1136\/annrheumdis-2015-208742","article-title":"Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study.","volume":"75","author":"Devauchelle-Pensec","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.semarthrit.2018.05.007","article-title":"Predictors of positive 18F-FDG PET\/CT-scan for large vessel vasculitis in patients with persistent polymyalgia rheumatica.","volume":"48","author":"Prieto-Pe\u00f1a","year":"2019","journal-title":"Semin Arthritis Rheum."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0255131","article-title":"The added value of 18f-FDG PET\/CT in the assessment of onset and steroid resistant polimyalgia rheumatica.","volume":"16","author":"Moya-Alvarado","year":"2021","journal-title":"PLoS One."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102764","article-title":"Novel positron emission tomography tracers for imaging of rheumatoid arthritis.","volume":"20","author":"van der Krogt","year":"2021","journal-title":"Autoimmun Rev."},{"key":"B52","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1007\/s12149-016-1080-0","article-title":"18F-fluoride PET\/CT for detection of axial involvement in ankylosing spondylitis: correlation with disease activity.","volume":"30","author":"Idolazzi","year":"2016","journal-title":"Ann Nucl Med."},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1186\/ar3792","article-title":"Bone formation rather than inflammation reflects ankylosing spondylitis activity on PET-CT: a pilot study.","volume":"14","author":"Bruijnen","year":"2012","journal-title":"Arthritis Res Ther."},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1903-1","article-title":"Performance of 18F-sodium fluoride positron emission tomography with computed tomography to assess inflammatory and structural sacroiliitis on magnetic resonance imaging and computed tomography, respectively, in axial spondyloarthritis.","volume":"21","author":"Raynal","year":"2019","journal-title":"Arthritis Res Ther."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1016\/j.spinee.2020.03.011","article-title":"Evaluation of the diagnostic performance of 18F-NaF positron emission tomography\/computed tomography in patients with suspected ankylosing spondylitis according to the assessment of spondyloarthritis international society criteria.","volume":"20","author":"Son","year":"2020","journal-title":"Spine J."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.3899\/jrheum.140059","article-title":"Detection of subclinical synovitis with macrophage targeting and positron emission tomography in patients with rheumatoid arthritis without clinical arthritis.","volume":"41","author":"Gent","year":"2014","journal-title":"J Rheumatol."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0222844","article-title":"Imaging disease activity of rheumatoid arthritis by macrophage targeting using second generation translocator protein positron emission tomography tracers.","volume":"14","author":"Bruijnen","year":"2019","journal-title":"PLoS One."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-1166-z","article-title":"B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis patients.","volume":"18","author":"Bruijnen","year":"2016","journal-title":"Arthritis Res Ther."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1070445\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T07:13:58Z","timestamp":1669792438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1070445\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,30]]},"references-count":58,"alternative-id":["10.3389\/fmed.2022.1070445"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.1070445","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,30]]},"article-number":"1070445"}}